James Maurice Youakim MD
Vice President, Clinical Development Acadia Pharmaceuticals
Join to view full profile
210 Carnegie CenterSuite 200Princeton, NJ 08540
Dr. Youakim is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Youakim is a psychiatrist based in Princeton, NJ, who completed his medical education and residency at Baylor College of Medicine, graduating in 1989. His scholarly work includes several publications on the treatment of Rett syndrome with the drug trofinetide, featuring notable studies published in journals such as Nature Medicine and Pediatric Neurology. His research has been cited multiple times, reflecting his active engagement in clinical research. Furthermore, he has participated in clinical trials focused on the use of pimavanserin for managing dementia-related psychosis and addressing agitation and aggression in Alzheimer's disease patients.
Education & Training
Baylor College of MedicineResidency, Psychiatry, 1989 - 1993- Baylor College of MedicineClass of 1989
Certifications & Licensure
PA State Medical License 1993 - 2026
American Board of Psychiatry and Neurology Psychiatry
American Board of Sleep MedicineSleep Medicine
Clinical Trials
- A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
- Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
- A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease Start of enrollment: 2017 Feb 23
Publications & Presentations
PubMed
- A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy...Mona Darwish, Amy Yamamoto, Yvonne Adegbenle, Ravi Tejwani, Yonghua Chen
Advances in Therapy. 2026-04-01 - 6 citationsResults from the phase 2/3 DAFFODIL study of trofinetide in girls aged 2-4 years with Rett syndrome.Alan K Percy, Robin Ryther, Eric D Marsh, Jeffrey L Neul, Timothy A Benke
Med. 2025-06-13 - 3 citationsAssessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical Trials.Amy M Barrett, Oyebimpe Olayinka-Amao, Susan Martin, Dilesh Doshi, Kathie M Bishop
Clinical Therapeutics. 2025-03-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
